NOT FOR DISTRIBUTION
Header cover image

Market Cap

CA$156.8m

Last Updated

2021/05/12 23:24 UTC

Data Sources

Company Financials

Executive Summary

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has ImmunoPrecise Antibodies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IPA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IPA's weekly volatility (13%) has been stable over the past year.


Market Performance


7 Day Return

-19.1%

IPA

-3.9%

CA Life Sciences

-0.8%

CA Market


1 Year Return

102.0%

IPA

46.4%

CA Life Sciences

38.7%

CA Market

Return vs Industry: IPA exceeded the Canadian Life Sciences industry which returned 48.2% over the past year.

Return vs Market: IPA exceeded the Canadian Market which returned 36.3% over the past year.


Shareholder returns

IPAIndustryMarket
7 Day-19.1%-3.9%-0.8%
30 Day-46.5%-4.1%0.2%
90 Day-53.8%-8.3%5.5%
1 Year102.0%102.0%46.7%46.4%43.3%38.7%
3 Year92.5%92.5%105.1%103.9%27.3%15.2%
5 Yearn/a202.1%198.4%57.2%33.6%

Long-Term Price Volatility Vs. Market

How volatile is ImmunoPrecise Antibodies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ImmunoPrecise Antibodies undervalued compared to its fair value and its price relative to the market?

4.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IPA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IPA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IPA is unprofitable, so we can't compare its PE Ratio to the North American Life Sciences industry average.

PE vs Market: IPA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPA is good value based on its PB Ratio (4.3x) compared to the XN Life Sciences industry average (7.1x).


Future Growth

How is ImmunoPrecise Antibodies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

8.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmunoPrecise Antibodies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has ImmunoPrecise Antibodies performed over the past 5 years?

-16.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IPA is currently unprofitable.

Growing Profit Margin: IPA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPA is unprofitable, and losses have increased over the past 5 years at a rate of 16.3% per year.

Accelerating Growth: Unable to compare IPA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (19.5%).


Return on Equity

High ROE: IPA has a negative Return on Equity (-10.08%), as it is currently unprofitable.


Financial Health

How is ImmunoPrecise Antibodies's financial position?


Financial Position Analysis

Short Term Liabilities: IPA's short term assets (CA$24.5M) exceed its short term liabilities (CA$7.2M).

Long Term Liabilities: IPA's short term assets (CA$24.5M) exceed its long term liabilities (CA$4.1M).


Debt to Equity History and Analysis

Debt Level: IPA's debt to equity ratio (5.4%) is considered satisfactory.

Reducing Debt: IPA's debt to equity ratio has increased from 0.7% to 5.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IPA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 18.1% each year


Dividend

What is ImmunoPrecise Antibodies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IPA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Jennifer Bath

3.25yrs

Tenure

CA$1,055,092

Compensation

Dr. Jennifer Lynne Bath, Ph.D, has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018. Dr. Bath served as the Global Director of Client Relations at Ald...


CEO Compensation Analysis

Compensation vs Market: Jennifer's total compensation ($USD872.20K) is above average for companies of similar size in the Canadian market ($USD156.15K).

Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IPA's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: IPA's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IPA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.1%.


Top Shareholders

Company Information

ImmunoPrecise Antibodies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoPrecise Antibodies Ltd.
  • Ticker: IPA
  • Exchange: TSXV
  • Founded: 1983
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$156.804m
  • Shares outstanding: 19.17m
  • Website: https://www.immunoprecise.com

Location

  • ImmunoPrecise Antibodies Ltd.
  • 3204–4464 Markham Street
  • Victoria
  • British Columbia
  • V8Z 7X8
  • Canada

Listings


Biography

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/12 23:24
End of Day Share Price2021/05/12 00:00
Earnings2021/01/31
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.